dc.contributor.author | Cerro Herreros, Estefanía | |
dc.contributor.author | González Martínez, Irene | |
dc.contributor.author | Moreno, Nerea | |
dc.contributor.author | Espinosa Espinosa, Jorge | |
dc.contributor.author | Fernández Costa, Juan M. | |
dc.contributor.author | Colom Rodrigo, Anna | |
dc.contributor.author | Overby, Sarah J. | |
dc.contributor.author | Seoane Miraz, David | |
dc.contributor.author | Poyatos García, Javier | |
dc.contributor.author | Vilchez, Juan J. | |
dc.contributor.author | López de Munain Arregui, Adolfo José | |
dc.contributor.author | Varela, Miguel A. | |
dc.contributor.author | Wood, Matthew J. | |
dc.contributor.author | Pérez Alonso, Manuel | |
dc.contributor.author | Llamusí, Beatriz | |
dc.contributor.author | Artero, Rubén | |
dc.date.accessioned | 2021-10-25T07:42:18Z | |
dc.date.available | 2021-10-25T07:42:18Z | |
dc.date.issued | 2021-12-03 | |
dc.identifier.citation | Molecular Therapy-Nucleic Acids 26 : 174-191 (2021) | es_ES |
dc.identifier.issn | 2162-2531 | |
dc.identifier.uri | http://hdl.handle.net/10810/53616 | |
dc.description.abstract | Myotonic dystrophy type 1 (DM1) is a rare neuromuscular disease caused by expansion of unstable CTG repeats in a non-coding region of the DMPK gene. CUG expansions in mutant DMPK transcripts sequester MBNL1 proteins in ribonuclear foci. Depletion of this protein is a primary contributor to disease symptoms such as muscle weakness and atrophy and myotonia, yet upregulation of endogenous MBNL1 levels may compensate for this sequestration. Having previously demonstrated that antisense oligonucleotides against miR-218 boost MBNL1 expression and rescue phenotypes in disease models, here we provide preclinical characterization of an antagomiR-218 molecule using the HSALR mouse model and patient-derived myotubes. In HSALR, antagomiR-218 reached 40-60 pM 2weeks after injection, rescued molecular and functional phenotypes in a dose- and time-dependent manner, and showed a good toxicity profile after a single subcutaneous administration. In muscle tissue, antagomiR rescued the normal subcellular distribution of Mbnl1 and did not alter the proportion of myonuclei containing CUG foci. In patient-derived cells, antagomiR-218 improved defective fusion and differentiation and rescued up to 34% of the gene expression alterations found in the transcriptome of patient cells. Importantly, miR-218 was found to be upregulated in DM1 muscle biopsies, pinpointing this microRNA (miRNA) as a relevant therapeutic target. | es_ES |
dc.description.sponsorship | This work was funded by research grants from Instituto de Salud Carlos III, including funds from FEDER, to M.P.-A. and B.L. (PI17/00352) and HR17-00268 (TATAMI project) from the “la Caixa” Banking Foundation to R.A. I.G.-M. was funded by the Precipita Project titled “Desarrollo de una terapia innovadora contra la distrofia miotónica,” E.C.-H. and J.M.F.-C. were supported by the post-doctoral fellowships APOSTD/2019/142 and APOSTD/2017/088 from the Fondo Social Europeo for science and investigation, while J.E.-E. was the recipient of a Santiago Grisolia fellowship (Grisolip2018/098) from the Generalidad Valenciana. Part of the equipment employed in this work has been funded by Generalitat Valenciana and co-financed with ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020). Antibody MB1a (4A8) was provided by MDA Monoclonal Antibody Resources | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | CTG repeat expansions | es_ES |
dc.subject | MBNL1 protein | es_ES |
dc.subject | alternative splicing | es_ES |
dc.subject | antisense oligonucleotide | es_ES |
dc.subject | microRNAs | es_ES |
dc.subject | myotonic dystrophy | es_ES |
dc.subject | therapeutic gene modulation | es_ES |
dc.subject | tissue distribution | es_ES |
dc.subject | transcriptomics | es_ES |
dc.title | Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0) | es_ES |
dc.rights.holder | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.relation.publisherversion | https://www-sciencedirect-com.ehu.idm.oclc.org/science/article/pii/S2162253121001852?via%3Dihub#! | es_ES |
dc.identifier.doi | 10.1016/j.omtn.2021.07.017 | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |